Literature DB >> 27730307

Calcium oxalate urolithiasis in children: urinary promoters/inhibitors and role of their ratios.

Daniel Turudic1, Danica Batinic2, Anja Tea Golubic3, Mila Lovric4, Danko Milosevic5.   

Abstract

Diagnostic criteria for determination of inclination towards idiopathic calcium oxalate (CaOx) urolithiasis based on biochemical urine parameters are not sufficiently well defined in children. The aim of this study was to determine the risk of CaOx urolithiasis in children from concentrations of calcium, oxalate, citrate, and glycosaminoglycans in urine and their ratios, all standardized in respect to creatinine. We collected and analyzed 24-h urine samples of children with CaOx urolithiasis (n = 61) and compared with urine samples of matched control group of healthy children (n = 25). The study has showed that all stone formers have higher excretion of calcium (mmol/mmol creatinine), calcium/citrate (mol/mmol), and oxalate/(citrate × glycosaminoglycans) ratio (mol Ox × mol cr)/(mol Cit × g GAGs). ROC analysis of these variables gave criteria (>0.28, >1.07, and >0.08, respectively) for distinguishing stone formers from healthy children. Biochemical urine parameters and their ratios (calcium, calcium citrate, and oxalate/(citrate × glycosaminoglycans) enable one to discriminate idiopathic calcium oxalate stone formers from healthy children. Oxalate/(citrate × glycosaminoglycans) ratio per se can serve as an independent risk for stone formation.
CONCLUSION: Using biochemical urine parameters and their ratios such as calcium, calcium/citrate, and oxalate/(citrate × glycosaminoglycans) enables one to determine diagnostic criteria towards idiopathic calcium oxalate urolithiasis in children. What is known: • The role of urine calcium as a promoter in calcium oxalate urolithiasis is well established. • Seldom used calcium/citrate ratio is acknowledged as a risk factor for calcium/oxalate urolithiasis. What is new: • The values of calcium and citrate in clinically and genetically proven idiopathic calcium oxalate urolithiasis make calcium/citrate ratio useful for diagnostic purposes in such stone formers. • Rarely used calcium independent oxalate/(citrate x glycosaminoglycans) ratio serves as the second best high specificity marker for idiopathic calcium oxalate urolithiasis.

Entities:  

Keywords:  Calcium; Children; Citrate; Glycosaminoglycans; Oxalate; Urolithiasis

Mesh:

Substances:

Year:  2016        PMID: 27730307     DOI: 10.1007/s00431-016-2792-9

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  25 in total

1.  Role of inhibitor deficiency in urolithiasis. I. Rationale of urinary magnesium, citrate, pyrophosphate and glycosaminoglycan determinations.

Authors:  M Akinci; T Esen; T Koçak; C Ozsoy; S Tellaloğlu
Journal:  Eur Urol       Date:  1991       Impact factor: 20.096

2.  Urinary glycosaminoglycans and glycoproteins in a calcium oxalate crystallization system.

Authors:  Ngork Wah Poon; Mayur Danny I Gohel
Journal:  Carbohydr Res       Date:  2011-09-29       Impact factor: 2.104

3.  Urinary glycosaminoglycan excretion in urolithiasis.

Authors:  T Akçay; D Konukoğlu; Y Dínçer
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

4.  Mutations in DHDPSL are responsible for primary hyperoxaluria type III.

Authors:  Ruth Belostotsky; Eric Seboun; Gregory H Idelson; Dawn S Milliner; Rachel Becker-Cohen; Choni Rinat; Carla G Monico; Sofia Feinstein; Efrat Ben-Shalom; Daniella Magen; Irith Weissman; Celine Charon; Yaacov Frishberg
Journal:  Am J Hum Genet       Date:  2010-09-10       Impact factor: 11.025

5.  Analysis of calcium, oxalate, and citrate interaction in idiopathic calcium urolithiasis in children.

Authors:  Danko Milosević; Danica Batinić; Pasko Konjevoda; Nenad Blau; Nikola Stambuk; Ljiljana Nizić; Kristina Vrljicak; Danko Batinić
Journal:  J Chem Inf Comput Sci       Date:  2003 Nov-Dec

6.  The value of urine citrate/calcium ratio in the estimation of risk of urolithiasis.

Authors:  D Batinic; D Milosevic; P Konjevoda; L Nizic; K Vrljièak; M Matkovic; D Batinic; L Grkovic
Journal:  Clin Nephrol       Date:  2004-06       Impact factor: 0.975

7.  Urinary excretion of citrate, glycosaminoglycans, magnesium and zinc in relation to age and sex in normal subjects and in patients who form calcium stones.

Authors:  A Trinchieri; A Mandressi; P Luongo; F Rovera; G Longo
Journal:  Scand J Urol Nephrol       Date:  1992

8.  Matrix glycosaminoglycan in urinary stones.

Authors:  S Nishio; Y Abe; A Wakatsuki; H Iwata; K Ochi; M Takeuchi; A Matsumoto
Journal:  J Urol       Date:  1985-09       Impact factor: 7.450

Review 9.  Diagnostic examination of the child with urolithiasis or nephrocalcinosis.

Authors:  Bernd Hoppe; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2008-12-23       Impact factor: 3.714

10.  Concave urinary crystallines: direct evidence of calcium oxalate crystals dissolution by citrate in vivo.

Authors:  Yun-Feng Shang; Meng Xu; Guang-Na Zhang; Jian-Ming Ouyang
Journal:  Bioinorg Chem Appl       Date:  2013-11-18       Impact factor: 7.778

View more
  3 in total

1.  Urinary sulfated glycosaminoglycan insufficiency and chondroitin sulfate supplement in urolithiasis.

Authors:  Thasinas Dissayabutra; Nuttiya Kalpongnukul; Kanokporn Chindaphan; Monpicha Srisa-Art; Wattanachai Ungjaroenwathana; Maroot Kaewwongse; Kroonpong Iampenkhae; Piyaratana Tosukhowong
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

Review 2.  The Impact of Water and Other Fluids on Pediatric Nephrolithiasis.

Authors:  Carmen Iulia Ciongradi; Florin Filip; Ioan Sârbu; Codruța Olimpiada Iliescu Halițchi; Valentin Munteanu; Iuliana-Laura Candussi
Journal:  Nutrients       Date:  2022-10-07       Impact factor: 6.706

3.  Age-Specific Excretion of Calcium, Oxalate, Citrate, and Glycosaminoglycans and Their Ratios in Healthy Children and Children with Urolithiasis.

Authors:  Daniel Turudic; Anja Tea Golubic; Mila Lovric; Marko Bilic; Danko Milosevic
Journal:  Biomolecules       Date:  2021-05-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.